Testing the regulatory framework in South Africa – a single-blind randomized pilot trial of commercial probiotic supplementation to standard therapy in women with bacterial vaginosis by Happel, Anna-Ursula et al.
RESEARCH ARTICLE Open Access
Testing the regulatory framework in South
Africa – a single-blind randomized pilot
trial of commercial probiotic
supplementation to standard therapy in
women with bacterial vaginosis
Anna-Ursula Happel1,2* , Ravesh Singh3,4, Nireshni Mitchev3, Koleka Mlisana3,4, Heather B. Jaspan1,5,
Shaun L. Barnabas1,6† and Jo-Ann S. Passmore1,2,4†
Abstract
Background: Bacterial vaginosis (BV) increases HIV risk and adverse reproductive outcomes. Standard-of-care (SOC)
for BV are antibiotics; however, cure rates are low. Probiotics for vaginal health may be useful in improving cure
and recurrence although the regulatory framework governing probiotics and the conduct of randomized clinical
trials to evaluate these has not been established in South Africa. We performed an exploratory single-blind trial
evaluating a commercial oral-vaginal-combination probiotic as adjunct to SOC for BV treatment.
Methods: Women with symptomatic vaginal discharge were screened for BV and common sexually transmitted
infections (STIs). BV+ (Nugent 7–10) but STI- women were randomized to vaginal metronidazole alone (n = 12) or to
metronidazole followed by a commercial oral/vaginal probiotic (n = 18). The primary qualitative outcome was to
test the regulatory landscape for conducting randomized probiotic trials in South Africa; and acceptability of vaginal
application by women. BV cure at 1 month (Nugent≤3) was the primary quantitative endpoint. Secondary
quantitative endpoints were BV recurrence, symptoms, vaginal microbiota and genital cytokine changes over 5
months post-treatment.
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Results: The South African Health Products Regulatory Authority (SAHPRA) reviewed and approved this trial. As
probiotics continue to be regulated as health supplements in South Africa, SAHPRA required a notification
application for this trial. Acceptability and adherence to the oral and vaginal application of the probiotic were high,
although women reported a preference for oral capsules. 44.8% of women cleared BV one-month post-treatment,
and no significant differences in BV cure (RR = 0.52, 95% CI = 0.24–1.16), recurrence, vaginal pH, symptoms,
microbiota or vaginal IL-1α concentrations were found between SOC and intervention groups in this pilot study
with an over-the-counter product.
Conclusion: Navigation of the SAHPRA registration process for evaluating a commercial probiotic in a randomised
trial laid the foundation for planned larger trials of improved probiotic products for vaginal health in South Africa.
Although adherence to the vaginally delivered probiotic was high, women preferred oral application and we
recommend that improvements in the content and method of application for future probiotics for vaginal health
should be considered.
Trial registration: This trial was registered on 17 October 2017 with the South African National Clinical Trial
Register (http://www.sanctr.gov.za/; BV-trial1; DOH-27-1117-5579).
Keywords: BV, Probiotics, Regulation, South Africa, SAHPRA, Vaginal health, Randomized trial
Background
Bacterial vaginosis (BV) is the most common genital
condition of women of reproductive age [1], defined by a
rapid shift in the composition of vaginal bacterial com-
munities from a Lactobacillus-dominated to a polymi-
crobial microbiota, compromising a mixture of diverse
anaerobes, such as Prevotella, Gardnerella, BVAB1,
Sneathia, and Megasphera spp. [2–4]. It increases risk of
adverse pregnancy outcomes [5, 6] and acquisition and
transmission of sexually transmitted infections (STIs),
including HIV [7, 8], possibly due to the associated geni-
tal inflammation [9]. Antibiotics remain the standard-of-
care (SOC) for treating BV although more than 50% of
women experience recurrent episodes within 6–12
months [10, 11]. While most countries treat BV as part
of syndromic management [12], more than 85% of BV
cases are asymptomatic but nonetheless associated with
significantly elevated genital inflammation [13]. In Af-
rica, where epidemics of BV, STIs and HIV converge
[14] and genital inflammation associated with even
asymptomatic BV may increase HIV risk [8, 15], an ur-
gent need to rethink and improve the SOC for treating
BV exists.
Several clinical studies have evaluated Lactobacillus-
containing probiotics as an adjunct to antibiotics in
treating BV [16, 17]. However, there is clinical equipoise
as to whether adjunctive probiotics improve BV cure
and/or recurrence rates [18]. As the microbial compos-
ition of the lower female genital tract (FGT) in health
and dysbiosis may be geo-adapted, with regional differ-
ences in diet, vaginal insertion, hygiene practices and
host genetics possibly shaping these [19–21], it is critical
to conduct trials in South Africa to test the effectiveness
of probiotics for vaginal health in a local context. While
randomized controlled trials (RCTs) assessing the effects
of probiotics on BV management have been performed
in several other African countries [22, 23], only one ex-
ploratory pilot study has recently been performed in
South Africa, although with a European product that is
not locally available [24].
In South Africa, the registration of medicines, probio-
tics and health supplements along with their use in clin-
ical trials is regulated by the South African
Health Products Regulatory Authority (SAHPRA), but
none of the > 100 currently available over-the-counter
(OTC) probiotics [25] has previously been formally
reviewed by SAHPRA and no trial evaluating the impact
of probiotics on health outcomes has been SAHPRA-
approved or acknowledged. Gaining understanding of
the regulatory framework for testing and introducing
new vaginal geo-adapted probiotics intended for vaginal
application is critical. Here, we describe the process and
acceptability of conducting an exploratory single-blind
trial in South African women diagnosed with BV. The
main qualitative outcome was to test the South African
regulatory framework and local acceptability of conduct-
ing probiotic trials for BV with vaginal application. BV
cure in women receiving probiotic in adjunct to SOC
compared to SOC only was an exploratory quantitative
outcome, together with understanding of adherence,
changes in vaginal pH, clinical symptoms, vaginal cyto-




This trial was submitted and approved by SAHPRA
(SAHRPA Ref 20,161,201; PI: S. Barnabas), the Univer-
sity of Cape Town’s (UCT) Human Research Ethics
Committee (HREC Ref 706/2016) and the South African
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National Health Research Ethics Council (NHREC Ref
4579) and registered with the South African National
Clinical Trials Register of the Department of Health
(DOH-27-1117-5579).
Eligibility criteria
Women were recruited from a South African public sec-
tor STI clinic (Spencer Road Clinic) and from the UCT
Student Wellness Centre in Cape Town, South Africa.
Eligible women were 18–45 years old and seeking care
for vaginal discharge. All eligible women were tested for
BV (by Nugent scoring) and STIs, including C. tracho-
matis, N. gonorrhoea, T. vaginalis, and M. genitalium by
TaqMan® Assays (Fast Track Diagnostics). Inclusion cri-
teria were being BV positive (Nugent 7–10) but negative
for any STI. Exclusion criteria included being pregnant,
breastfeeding, pelvic inflammatory disease, living with
HIV, having a known allergy to metronidazole, and/or
currently using any other antibiotics or natural remedies
in the urogenital area. Women who acquired an STI or
had recurrent BV over the course of the trial were
referred for treatment but not excluded, and any con-
comitant medication (including antibiotics) taken over
the course of the study was recorded. Study visits were
planned such that women were not menstruating nor re-
ported having unprotected sex or douching in the 48 h
prior to sampling. All women were tested for HIV
(Rapid Anti-HIV (1&2) test; InTec products, Inc., China)
and pregnancy (hCG Pregnancy test; Homemed™, South
Africa) at screening.
Sample size calculations
This was an exploratory study designed to establish
the regulatory landscape to conduct probiotic trials in
South Africa, with additional exploratory quantitative
analyses. We based our sample size calculation of 30
women on cure rates from previous studies [22, 26].
Petricevic et al. (2008) reported a decline in BV in
83% of intervention compared to 35% in control arm
participants after oral application of 300 mg clindamy-
cin for 7 days followed by vaginal capsules containing
109 CFU of L.casei rhamnosus for 7 days and Anukam
et al. (2006) reported cure rates of 88% in the treat-
ment group and 40% in the control group after ad-
ministering 500 mg metronidazole orally for 7 days
followed by oral administration of L.rhamnosus and
L.reuteri (each 109 CFU) for 30 days. In both studies,
cure rates were assessed 30 days after the last admin-
istration of the probiotics. Since we applied probiotics
both orally and vaginally and for 15 days, we expected
the cure rates to be similar. Thus, we anticipated a
sample size of 30 women (enrolled in a 2:3 ratio in
SOC: intervention arms) would detect the above dif-
ference in proportions (0.83 vs. 0.35) with 75% power
at α = 0.05, which we considered sufficient for this
pilot trial.
Randomisation and blinding
Randomisation was performed using the pseudorandom
number generator in Microsoft Excel 2016 (MT19937)
by research pharmacists at the UCT CRC who were not
involved with clinical procedures and/or screening pro-
cesses and only dispensed the investigational product.
Researchers and laboratory staff involved in sample and
data analysis were blinded to the randomisation process.
The research nurse who conducted the clinic visits was
not blinded as she interacted directly with participants.
After the database lock and a primary blinded analysis,
the unblinded treatment allocations were released.
Dosing regimens
Eligible women either received topical metronidazole
only (0.75% gel, 5 g vaginally, once a day for 5 days) or
topical metronidazole followed by a 15-day treatment
course of a probiotic marketed in South Africa to im-
prove vaginal health (intervention group), which in-
cluded 5 days of oral probiotic capsules followed by 10
days of oral capsules together with twice daily vaginal
spray. The oral capsules and each metered dose of the
vaginal spray contained lyophilized L. acidophilus, L.
rhamnosus GG, B. bifidum and B. longum at ≥2 × 109
colony-forming units (CFU).
Laboratory quality control of the probiotic lot used in the
study
The contents and concentrations of each microbial spe-
cies of the probiotic lot were confirmed prior to initi-
ation of the trial (Additional Figure 1). Briefly, one full
oral or vaginal dose was dissolved in Brain Heart Infu-
sion broth (supplemented with 0.1% starch and 1% yeast,
sBHI), serially diluted and plated in triplicates onto sBHI
agar plates. Plates were incubated at 37 °C for 48 h under
anaerobic conditions (using Oxoid™ AnaeroGen™ 2.5 L
Sachets, Thermo Fisher Scientific Inc., USA). The CFU
per well were counted and the average concentration
per dose was calculated. Contents were confirmed by
MALDI-TOF (MALDI Biotyper, Bruker Daltonik, USA).
Clinical procedures and sample collection
At screening, a vulvo-vaginal swab for STI testing and a
posterior fornix and lateral wall swab to screen for BV
by Nugent Scoring were collected. At enrolment (pre-
treatment), and 1, 3 and 5 months post-treatment, geni-
tal samples were collected in the following order under
speculum examination: (1) a vulvo-vaginal swab for STI
testing; (2) a posterior fornix and lateral wall swab to
screen for BV (by Nugent Scoring) and to measure vagi-
nal pH (using a colour-fixed indictor pH strip; Macherey
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Nagel); and (3, 4) two lateral wall swabs to measure
genital IL-1α (as marker of genital inflammation, by
ELISA) and vaginal microbiota (by qPCR). In addition,
women completed a questionnaire on demographics, re-
productive health and sexual behaviour at enrolment,
and a questionnaire assessing feasibility, acceptability
and adherence to the administered products, vaginal
symptoms and adverse events at follow up visits. Product
preference was assessed at the final visit by question-
naire (Additional File 1). Adherence was measured by
self-report in medication diaries and questionnaires, as
well as return of empty packages at the one-month
follow-up visit.
Testing for STIs and BV
The commercial TaqMan® FTD STD9 (Fast Track Diag-
nostics, Luxembourg) kit, performed as per manufac-
turer’s instructions, was used to test for N. gonorrhoeae,
C. trachomatis, T. vaginalis and M. genitalium. As posi-
tive controls, genomic DNA extracts from the following
ATCC® strains were included: N. gonorrhoeae (ATCC®
700825), C. trachomatis (ATCC® VR-885), T. vaginalis
(ATCC® 30001) and M. genitalium (ATCC® 33530). BV
was diagnosed by Gram staining of vaginal smears and
Nugent Scoring. Slides were assessed microscopically
and assigned a score between 0 and 10, with a score of
0–3 considered BV negative, 4–6 intermediate micro-
biota, and 7–10 BV positive.
Clinical outcomes
While this study was intended to test the regulatory land-
scape to conduct probiotic trials in South Africa and ac-
ceptability/preference of the probiotic administration for
vaginal health, BV cure rates were considered (defined as
having Nugent≤3 one-month post-treatment) as primary
quantitative endpoint. In addition, other secondary end-
points included adherence, recurrence, changes in vaginal
pH, concentrations of bacterial species contained in the
administered probiotic (L. acidophilus, L. rhamnosus, B.
bifidum and B. longum) and bacterial species associated
with vaginal health (L. crispatus, L. jensenii, L. iners, L. gas-
seri, L. vaginalis, L. mucosae) or BV (G. vaginalis, P. bivia,
BVAB2, Megasphaera 1 and A. vaginae), and IL-1α con-
centrations (as a bio-marker of genital inflammation) over
5 months post-treatment.
Measuring vaginal bacterial concentrations
Concentrations of vaginal Lactobacillus spp. (including L.
crispatus, L. jensenii, L. iners, L. gasseri, L. vaginalis, L.
mucosae), BV-associated organisms (including G. vagina-
lis, P. bivia, BVAB2, Megasphaera 1 and A. vaginae), and
bacterial species contained in the administered probiotic
product (including L. acidophilus, L. rhamnosus, B. bifi-
dum and B. longum) were assessed using commercially
available Applied Biosystems™ TaqMan® Assays (Thermo
Fisher Scientific Inc., USA; Assay IDs Ba04646245_s1,
Ba04646258_s1, Ba04646257_s1,, Ba04646234_s1 for
Lactobacillus spp. and Ba04646236_s1, Ba04646278_s1,
Ba04646229_s1, Ba04646230_s1, Ba04646222_s1 for BV-
associated species). For L. vaginalis (KF875988.1) and L.
mucoasae (NR_024994.1) Thermo Fisher Scientific de-
signed custom probes based on the referenced nucleotide
sequence. The TaqMan probe sequences for L. acidoph-
ilus and L. rhamnosus (Haarman and Knol [27]), as well as
B. bifidum and B. longum (Haarman and Knol [28]) were
previously published. Using an ABI 7500 Real-Time PCR
Detection System (Thermo Fisher Scientific Inc., USA),
we quantified each of the targets. The quantification was
performed using amplicons generated from plasmids for
each of the targets (TaqMan™ Vaginal Microbiota Extrac-
tion Control). Serial dilutions, ranging from 100 to 109
molecules per μl of sample were used to generate standard
curves. Bacterial concentrations were normalized to 16S
rRNA gene concentrations, as recommended by the
manufacturer.
Measuring cervicovaginal IL-1α concentrations
Samples were thawed on ice and filtered by centrifuging
at 1950 g for 10 min at 4 °C in SPIN-X® 0.2 μM cellulose
acetate filters to exclude mucus and debris prior to per-
forming the ELISA. Human IL-1α concentrations were
measured using a commercial ELISA (E-EL-H008,
Elabscience®, USA), according to the manufacturer’s in-
structions. IL-1α concentrations were calculated based
on the standard curve, using standards provided with
the kit. The detection range was 1.25–125 pg/mL, and
all values below the detection limit were recorded as half
of the lowest concentration measured.
Statistical analyses
GraphPad Prism6® (GraphPad Software, USA), STATA
version 11.0 (StataCorp, USA) and R were used for de-
scriptive and statistical analyses and to generate graphs.
Planned description of continuous variables with means,
medians and standard deviations, as appropriate, were
calculated. Categorical variables were described as pro-
portions. Mann-Whitney U tests were used to compare
groups of continuous variables and relative risk (RR) was
used for categorical variables. 95% confidence intervals
and p-values ≤0.05 were used to determine statistical
significance.
Results
Path to SAHPRA approval
This trial intended to explore the regulatory environ-
ment in South Africa governing probiotic trials, in order
to lay the foundation for future trials of novel probiotic
products. Prior to conducting this randomized trial, no
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probiotic trial had been approved by the regulatory au-
thorities in South Africa. Thus, discussions with SAH-
PRA authorities were initiated in March 2016, as a
decision on whether a full application for the trial was
necessary, given that this was a randomized trial with a
vaginally applied product, or whether a notification ap-
plication was required. Currently, already available OTC
probiotics (even those applied topically) are not consid-
ered or regulated as a medicine in South Africa but ra-
ther as a health supplement. Typically, the regulator
requires full applications for products not registered in
South Africa or for those not being used for their
registered indication, dose, or formulation. Alterna-
tively, SAHPRA notification is required for phase IV
clinical studies of an approved medication within its
approved dosage, formulation and indication. SAH-
PRA finally confirmed that the trial did not require a
full application but rather a notification application,
which was submitted to SAHPRA and approved
(SAHRPA Ref 20,161,201).
Cohort behavioural and biomedical characteristics
Between 30 October 2017 and 22 March 2018, a total of
96 women seeking care for vaginal discharge were
screened for eligibility (Fig. 1), of which the majority (n =
90) were recruited via the UCT Student Wellness Centre.
One woman tested HIV positive at screening, and thus
was excluded and referred for care. Of 95 women who
were eligible for screening, 43 women (45.3%) were con-
firmed to have BV (Nugent 7–10; Table 1). Given that we
recruited symptomatic women, this ratio confirms that va-
ginal discharge is a very imprecise tool for predicting the
presence of BV [14], with a positive predictive value of
only 45.3% in this cohort. In addition, 17.9% (17/95) had
an STI, with T. vaginalis (9.5%, 9/95) and C. trachomatis
(8.4%, 8/95) being the most common STIs detected. Of
the 43 BV positive women, 33 were eligible for
randomization (BV+ but STI-).
Of the 33 women who were eligible, three were not in-
terested in participating further. Therefore, 12/30 were
randomized to the SOC arm (vaginal metronidazole
alone; 5 days), while 18/30 were randomized to the inter-
vention arm (vaginal metronidazole for 5 days, followed
by 15 days of oral/vaginal probiotics). Randomised
women were a median age of 22 years (IQR 20–26 years)
old, predominantly single (26/30, 86.7%), and self-
identified as black (20/30, 66.7%). Their median age at
sexual debut was reported to be 17 years (IQR 16–
19 years) with a median of five lifetime sexual partners
(IQR 3–8), and reporting of oral sex was common (21/
30, 70.0%). About half (18/30) reported regular condom
use, and few (n = 4) reported previously being diagnosed
or treated for an STI (Table 2). Ninety-three percent
(28/30) reported a history of chronic vaginal discharge,
and more than half (20/30) reported previous use of pre-
scription medicine to reduce vaginal discharge and mal-
odour. Almost half (14/30) reported that they were
currently smoking, a factor that has previously been as-
sociated with the risk of BV [29–31]. Similarly, vaginal
cleansing practices have been described as risk factor for
BV [32–34], and more than half (17/30) reported prac-
ticing some kind of cleansing, including douching, using
their fingers, water or soap to clean their vaginas intern-
ally (Table 2). More than half used tampons while men-
struating, suggesting that they may likely be comfortable
with the vaginal application of the probiotic (Table 2).
None of the socio-behavioural characteristics evaluated
differed by study arm.
Adherence and safety
Women attended a total of 143 visits, with the majority (25/
30) completing all visits (Fig. 1) and all women (30/30) com-
pleting the entire five-day course of metronidazole. All
women randomised to the probiotic (18/18) completed the
course of oral probiotic capsules, and the majority (16/18)
also completed the vaginal probiotic spray.
Overall, a total of 110 adverse events (AEs) were re-
corded over the course of the study. Most were mild
(WHO grade 1–2, 109/110, 99.1%) and unrelated to
study product use (76.4%; 84/110), including head-
aches (n = 20), flu-like symptoms (n = 18), STI acquisi-
tion, including C. trachomatis (n = 8), T. vaginalis (n =
7), M. genitalium (n = 5) and N. gonorrhoea (n = 1),
menstrual pain (n = 7), gastro-intestinal complaints
(n = 5), temporary vaginal discomfort related to vagi-
nal intercourse (n = 7), anaemia (n = 2), cat allergy
(n = 1), buttock pain (n = 1), and anxiety (n = 1). It was
concerning that more than half of the women (53.3%,
16/30) acquired an STI over the course of the study,
supporting that BV is considered a risk factor for ac-
quisition of STIs [7, 8]. Although BV has also been de-
scribed as risk factor for urinary tract infections [35],
none were reported by the participants throughout the
course of the study.
Of AEs considered to be related to study products
(n = 26), the majority was associated with vaginal
metronidazole use and included previously describe
side effects of vaginal metronidazole gel [36], including
vaginal itching/irritation (9/30, 30.0%), candida infec-
tions (5/30, 16.7%), discomfort (3/30, 10.0%), increased
discharge (2/30, 6.7%), spotting (1/30, 3.3%), or consti-
pation (1/30, 3.3%). One third of the women adminis-
tering probiotics (5/18, 27.8%) reported AEs after
vaginal probiotic use, including vaginal itching/discom-
fort (2/18, 11.1%), increased vaginal discharge (1/18,
5.6%), increased nipple sensitivity (1/18, 5.6%), and
nausea (1/18, 5.6%).
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Acceptability
More than half of the women (9/15, 60.0%) reported that
they liked using the combination probiotic because it
was easy to use or resulted in improved vaginal symp-
toms (Fig. 2a). Most women (12/15, 80.0%) reported that
they preferred the oral capsule over the vaginal spray
(Fig. 2b). Women reported that the vaginal spray was
difficult to use, “messy and smelly” or that AEs occurred.
The vast majority (14/15, 93.3%) believed that they re-
ceived some benefit from this product and would buy it,
primarily to prevent rather than to treat BV (Fig. 2c).
The majority (13/15, 86.7%) also said they would recom-
mend it to other women. In terms of future product de-
sign, women reported that they would prefer a probiotic
with oral application rather than a combination of oral
and vaginal or vaginal only administration (Fig. 2d). If
vaginal administration was required, women responded
that they would prefer a tablet or gel rather than a tam-
pon, spray or capsule. Women reported that they would
prefer to buy the probiotic at pharmacies (12/15, 80.0%)
compared to health stores, a grocery store or clinic
(Fig. 2e). Women reported a preference for asking
Fig. 1 Consort diagram. A total of 96 women with symptomatic discharge were screened for eligibility Participants were tested for BV by Nugent
Scoring on for STIs (including C. trachomatis, T. vaginalis, M. genitalium and N. gonorrhoeae) by Multiplex PCR. Eligible participants (BV positive but
STI negative) were randomly assigned to the SOC (metronidazole only) or intervention arm (metronidazole plus probiotic). Follow-up visits took
place 1, 3 and 5months post-treatment. LTFU = lost to follow up
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nurses (13/15, 86.6%) or doctors (11/15, 73.3%) for ad-
vice about using probiotics for vaginal health rather than
pharmacists or self-help on the internet (Fig. 2f). It was
also important to note that none of the women reported
to be willing to spend more than 200 South African rand
(ZAR; ~USD11.40; 1:0.06), which was less than the cost
of the probiotic tested in this trial (costing ZAR280;
~USD16.00).
Comparing clinical outcomes in SOC and intervention
arms
This trial was intended as an exploratory study to test
the local regulatory environment and acceptability of va-
ginal probiotics. However, we also conducted an ex-
ploratory intention-to-treat (ITT) analysis to estimate
possible benefits of administration of this locally sourced
probiotic on clinical outcomes. The majority of women
Table 1 Screening results
Age participant [years, median (IQR)] 22 (20–25)




Bacterial vaginosis (Nugent Score 7–10) [% (n/N)] a 45.3 (43/95)
Bacterial and protozoal infections [% (n/N)]a
T. vaginalis 9.5 (9/95)
C. trachomatis 8.4 (8/95)
M. genitalium 3.2 (3/95)
N. gonorrhoea 2.1 (2/95)
Eligible (BV+/STI-) [% (n/N)]a 34.7 (33/95)
aOne participant tested HIV positive, thus screening was aborted
Table 2 Cohort characteristics at enrolment
SOC n = 12 Intervention n = 18
Age participant [years, median (IQR)] 23 (21–34) 22 (20–26)
Self-identified race [% (n)]
Black 58.3 (7) 72.2 (13)
Coloured 25.0 (3) 16.7 (3)
White 16.7 (2) 11.1 (2)
Age menarche [years, median (IQR)] 12 (11–15) 14 (13–16)
Marital Status [% (n)]
Single 83.3 (10) 88.9 (16)
Married 8.3 (1) –
Separated/Divorced 8.3 (1) 11.1 (2)
Pregnancies and contraception [% (n)]
Ever been pregnant 25.0 (3) 27.8 (5)
Currently using hormonal contraception 33.3 (4) 38.9 (7)
Reported current smoking [% (n)] 50.0 (6) 44.4 (8)
Sexual risk behaviour and sexual health
Age of sexual debut [median (IQR)] 18 (17–18) 17 (16–19)
Number of lifetime partners [median (IQR)] 5 (3–8) 4 (3–8)
Oral sex during last 6 months [% (n)] 58.3 (7) 77.8 (14)
Regular condom use during last 6 months [% (n)] 66.7 (8) 55.6 (10)
Ever been diagnosed or treated for a STI [% (n)] 8.3 (1) 16.7 (3)
Partner or participant STI in last 6 month [% (n)] – 16.7 (3)
Long-term history of vaginal discharge [% (n)] 83.3 (10) 100 (18)
Vaginal product use [% (n)]
Use of medicine from doctor/nurse 58.3 (7) 72.2 (13)
Use of tampon 25.0 (3) 16.7 (3)
Cleansing with fingers 16.7 (2) 11.1 (2)
Cleansing with water 25.0 (3) 33.3 (6)
Douching to clean vagina – 16.7 (3)
Cleansing with soap 8.3 (1) 5.6 (1)
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reported an improvement of their vaginal symptoms
post-treatment, including discharge, colour and odour,
with similar rates in the SOC and intervention arms
(Table 3). Of these, the majority reported a decrease of
vaginal discharge, and more than half reported a change
in smell and/or colour of the discharge, independently of
treatment arm.
The overall BV cure rate (defined as achieving a
Nugent score 0–3) was 44.8% at month one, 46.4% at
month three and 53.8% at month five. BV cure rates
tended to be higher in the SOC arm (63.6%; 7/11)
compared to the intervention arm (33.3%; 6/18; RR =
0.52, 95% CI = 0.24–1.16, p = 0.109) 1 month post-treat-
ment (Fig. 3a). However, almost half of the cured
women in the SOC arm (3/7) subsequently re-tested BV
positive (Nugent 7–10) at month 3, while more than half
of the cured women in the intervention arm (4/6)
remained BV negative until the end of the trial.
In the SOC arm, 6/11 (54.5%) women had a vaginal
pH < 4.5 1 month after treatment, compared to 11/18
(61.1%) in the intervention group (RR = 1.12, 95% CI =
0.58–2.15, p = 0.733; Fig. 3b). Similarly, no significant
Fig. 2 Acceptability and preference of probiotics for vaginal health. At the final visit, participants completed a questionnaire to assess their (a) opinion about
the oral/vaginal probiotic they used during the trial, (b) why their preferred the oral or vaginal application, (c) their perceived benefits and whether they would
use it again or recommend it to another woman, (d) their application preference for the development of a future probiotic for vaginal health, (e) where they
would want to buy it and (f) from whom they would like to get advice regarding the use of probiotics for vaginal health
Table 3 Reported vaginal symptoms post-treatment
Month 1 Month 3
SOC Intervention RR (95%CI)a
p-value
SOC Intervention RR (95%CI)a
p-value
Discharge improvement [%(n/N)] 83.3 (10/11) 77.8 (14/18) 0.86 (0.63–1.17)
p = 0.324
83.3 (10/12) 81.3 (13/16) 0.96 (0.69–1.34)
p = 0.886
Less discharge 90.0 (9/10) 78.6 (11/14) 0.87 (0.62–1.23)
p = 0.438
90.0 (9/10) 61.5 (8/13) 0.68 (0.42–1.10)
p = 0.118
Change in colour 50.0 (5/10) 57.1 (8/14) 1.14 (0.53–2.46)
p = 0.733
70.0 (7/10) 46.2 (6/13) 0.66 (0.32–1.35)
p = 0.253
Change in smell 70.0 (7/10) 71.4 (10/14) 1.02 (0.60–1.72)
p = 0.940
80.0 (8/10) 61.5 (8/13) 0.77 (0.45–1.31)
p = 0.332
aRelative Risk (RR) and 95% Confidence interval (CI) were used to compare groups
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difference between the SOC and intervention arms were
noted at later time points. Nugent scores correlated sig-
nificantly with vaginal pH (Spearman rho = 0.71; p =
0.0001).
Evaluating the presence of probiotic species in the
genital tract
To establish a framework on whether the bacterial spe-
cies contained in the oral/vaginal probiotic colonised the
FGTs of women, concentrations of L. rhamnosus, L.
acidophilus, B. bifidum and B. longum were measured
before and after treatment (Fig. 4a). The majority of
women (20/30) had detectable concentrations of L. acid-
ophilus at baseline, although few had detectable levels of
L. rhamnosus (2/30), B. bifidum (2/30) and B. longum
(8/30). However, we found no evidence of colonization
of any of the bacterial species contained in the probiotic
formulation post-treatment (Fig. 4a).
Fig. 3 BV status and vaginal pH in the SOC and intervention group. a BV status was determined by Nugent scoring at screening, and one, three
and five months post-treatment. Nugent Score 0–3 = BV negative (white area); 4–6 = BV intermediate (yellow) and 7–10 = BV positive (orange). b
Vaginal pH was measured using color-fixed indicator strips one, three and five months post-treatment. A vaginal pH < 4.5 (white area) is seen as
protective. Each participant is represented by a symbol-coded dot, and the summaries show median and interquartile range
Fig. 4 Quantities of vaginal bacterial species in the SOC and intervention group. a Bacterial species contained in the administered probiotic, including
L. acidophilus, L. rhamnosus, B. bifidum and B. longum, vaginal Lactobacillus spp., including L. crispatus, L. gasseri, L. jensenii, L. vaginalis, L. mucosae and L.
iners (b) and BV-associated bacteria, including G. vaginalis, P bivia, Atopobium, BVAB2 and Megasphera (c) were measured by qPCR and normalised to
total 16S rRNA gene concentration at month 0 (enrolment) and 1, 3 and 5 months post-treatment. Values were log-transformed and supervised
clustering was used to generate the heatmap. Each row shows one participant. Darkest blue indicates levels below detection limit. White data points
indicate missing data. Light purple indicates participants from the SOC and dark purple participants from the intervention group
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Commensal Lactobacillus and BV-associated communities
following BV treatment
Most women had very low concentrations of L. crispa-
tus, L. gasseri, L. jensenii and L. vaginalis before treat-
ment, as expected (Fig. 4b). While some women showed
increased concentrations of beneficial vaginal Lactobacil-
lus spp. 1 month after treatment, others did not, and this
did not differ by study arm. L. mucosae and L. iners were
more commonly detected and concentrations were gen-
erally higher than those of other Lactobacillus spp.
(Fig. 4b).
In line with their BV diagnosis, most women had de-
tectable concentrations of G. vaginalis (26/30), P. bivia
(21/30) and A. vaginae (29/30) pre-treatment (Fig. 4c).
The concentrations of these BV-associated bacteria
remained high throughout the trial despite BV treat-
ment, both in the SOC and intervention arm. While
most women had BVAB2 (22/30) and some Megasphera
(14/30) present pre-treatment, only some women lost or
had decreased quantities of these bacterial species post-
treatment, irrespective of study arm (Fig. 4c).
Genital inflammation and interactions between the host
and vaginal microbiota
Genital IL-1α, a marker of inflammation [37], decreased
after treatment in most women, albeit not significantly.
However, levels of IL-1α increased again quickly to those
measure pre-treatment (Fig. 5). Adjusting for STIs ac-
quired during the trial had no impact on this observa-
tion. While IL-1α concentrations did not correlate with
presence or absence of most Lactobacillus spp. and none
of the BV-associated organisms, it correlated with L.
iners concentrations 1 month (Spearman r = 0.368, p =
0.049), and 3 months post-treatment (Spearman r =
0.373, p = 0.055).
Discussion
In the present study, we evaluated the regulatory envir-
onment for conducting probiotic trials in South Africa.
SAHPRA required a notification application, as the
probiotic was available OTC in South Africa and consid-
ered a health supplement. The use of a vaginal/oral pro-
biotic combination was well accepted among South
African women included in this exploratory study and
was associated with few product-related AEs. While this
study was not sufficiently powered to test efficacy of this
convenient OTC probiotic in South African women, we
observed no beneficial clinical effect of this adjunctive
probiotic compared to vaginal metronidazole alone as
SOC. Nonetheless, this exploratory trial provided valu-
able lessons for future probiotic trials of the same dis-
ease entity in the same population, with improved
products and adequate sample sizes.
With regards to the regulatory landscape, SAHPRA
regulates OTC probiotics currently as health supple-
ments, independently of their route of administration
and health claims being made, but labels must state that
“This unregistered medicine has not been evaluated by
the SAHPRA for its quality, safety or intended use” [38].
In contrast, all health claims for probiotics in the Euro-
pean Union have to be authorized by the European Food
Safety Authority (EFSA). Any statement suggesting a re-
lationship between a product and health outcomes is
considered a health claim, including using the term
“probiotic” on a product label [39]. Thus far, EFSA has
rejected all submitted health claims for probiotics [39].
Further, vaginally applied probiotics used to be regulated
as medical devices, with even stricter regulations, stan-
dards and certification processes than orally applied
products. Recent changes in the Medical Device Regula-
tion state that living organisms are no longer acceptable
as ingredients for medical devices from 2020, thus cur-
rently marketed vaginally applied probiotic products will
have to either be re-classified or transferred to a new
product category [40]. In the United States, most probio-
tics are classified as foods or dietary supplements, which
are required to comply with Good Manufacturing Prac-
tice guidelines, but no quality or efficacy testing is re-
quired [39]. As in the European Union, no disease-
specific claims can be made on labels of dietary
Fig. 5 Levels of the inflammatory marker IL-1⍺ in the FGT of participants in the SOC and intervention arm. IL-1⍺ was measured by ELISA in FGT
secretions of SOC and intervention group participants pre-treatment and 1, 3 and 5months post-treatment. Each participant is represented by a
symbol-coded dot. The percentages compared to the IL-1⍺ level measured pre-treatment (month 0) are displayed. The shaded area indicates a
decrease in IL-1⍺ post-treatment. The summary shows the median and interquartile range
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supplements, but functional claims, such as “improves
vaginal health”, can be made when accompanied by a
disclaimer [39]. Thus, while SAHPRA, the regulatory
body in South Africa, seems to be more concerned with
product safety than misleading claims, sound scientific
approaches should be required to demonstrate specific
health benefits of commercially available probiotics to
more closely align with regulatory bodies in Europe and
the United States. Previous South African studies have
shown poor correlation between label claims and actual
probiotics content [41], thus post-market surveillance
should be mandatory as well.
With regards to product design, women reportedly
preferred the oral over the vaginal application of the
probiotic, as the administration of the vaginal spray was
uncomfortable and messy. Thus, for future probiotic
product design women’s preferences should be taken
into consideration and probiotics containing well-
selected vaginal Lactobacillus spp. should be adminis-
tered orally. If topical administration is required, a vagi-
nal tablet or gel would be preferred over a spray.
Importantly, women were not willing to spend more
than ZAR 200 (~USD11.40) for one treatment course.
Given that > 60% of South African households earned
less than ZAR 6367 (~USD368.55) per month according
to the latest Census [42], the cost of one treatment
course of the administered product per individual (ZAR
280; ~USD16.00) would use up 4.4% of the monthly in-
come of those South African households. This highlights
the need for the development of cheaper probiotics for
vaginal health, making them available for those most in
need of it.
The selected OTC oral/vaginal probiotic, like all those
available in South Africa, does not contain Lactobacillus
spp. that are commonly present in the FGT and associ-
ated with vaginal health, internationally and in South Af-
rican women, such as L. crispatus, L. gasseri or L.
jensenii [19, 43]. Others have shown that vaginal Lacto-
bacillus spp. are highly adapted to this ecological niche
[44], and since the product did not contain those highly
adapted Lactobacillus spp., they might have failed to
colonize, which is in agreement with our microbiological
results. For a successful colonization and subsequent
ability to confer a health benefit to the host, the bacteria
need to fulfil a broad range of other criteria including
adherence to vaginal epithelial cells, production of lactic
acid, decrease of vaginal pH, decrease of inflammatory
cytokines, and inhibition of BV-associated bacteria, such
as G. vaginalis or P. bivia [43]. We have isolated and
characterised the Lactobacillus strains contained in this
OTC phenotypically and compared their characteristics
to vaginal Lactobacillus strains from healthy South Afri-
can women [43]. We did in fact find that vaginal Lacto-
bacillus strains largely performed better in these in vitro
assays than the strains currently used in probiotics for
vaginal health, suggesting that it might not be ideal to
include these strains in commercial probiotics for vagi-
nal health.
Based on this experience with the South African regu-
latory body SAHPRA, we have some important insights
for the design of future probiotic trials in South Africa.
Clinical studies should test for BV cure shortly after
treatment completion to minimize the likelihood that
women have a recurrent BV event, in order to differenti-
ate BV cure rates from confounding repeat episodes.
Further, including a comparison with vaginal metronida-
zole gel alone or in combination with probiotic is more
similar to a superiority trial rather than placebo-
controlled [45], which is likely to make an efficacy trial
with probiotics more difficult to power. Finally, we used
vaginal metronidazole gel instead of oral metronidazole,
which is more commonly used in South Africa for treat-
ing BV due to its lower cost. However, vaginal metro-
nidazole gel is thought to be more effective and have
less systemic side effects than the cheaper oral formula-
tion [46, 47], which again should be taken into account
when performing power calculations.
One interesting microbiological observation made dur-
ing this study was that concentrations of vaginal L. iners
correlated positively with the inflammatory cytokine IL-
1α. This supports literature suggesting that L. iners is
not necessarily as beneficial as other common vaginal
Lactobacillus spp. [48–50]. L. iners is often present dur-
ing BV, has complex nutritional requirements compared
to other vaginal Lactobacillus spp., and encodes ineroly-
sin, a pore-forming toxin that is related to G. vaginalis-
encoded vaginolysin [50]. The high inflammation associ-
ated with L. iners in our study suggests that rather than
only treating women with BV, also women with an L.
iners-dominated microbiota and high genital inflamma-
tion could benefit from well-designed probiotics for va-
ginal health.
An important limitation of this study was the small
number of participants; although this was intended as an
exploratory study to test the regulatory environment in
South Africa and the acceptability/preference of oral ver-
sus topical application. In addition, administration of the
study drugs was self-reported and vaginal pH was not
being measured pre-treatment. It was also unexpected
that genital tract IL-1α levels differed at baseline be-
tween randomized groups, which is difficult to explain.
Further, no 16S rRNA gene sequencing to evaluate rela-
tive vaginal bacterial abundance was performed, neither
was bacterial culture.
Conclusions
In a region with some of the highest rates of BV, STIs
and HIV, it is critical that the local regulatory
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environment for conducting randomized trials of
planned novel probiotic products is established. This
randomized single-blinded trial provided important
regulatory and clinical considerations critical in the de-
sign of future clinical trials, with larger sample sizes
intended for safety and efficacy endpoints. This explora-
tory trial did suggest that oral and vaginal OTC probio-
tics were generally safe and acceptable in South African
women with BV. Due to the critical need to manage BV
better internationally and in South Africa, future double-
blind, randomized, placebo-controlled trials, using a pro-
biotic product containing beneficial, well-characterised
vaginal Lactobacillus strains are needed to conclusively
determine the efficacy of adjunctive probiotics on BV
cure and recurrence in South African women.
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